

Policy	MM-016
Effective Date	09/01/2024
Reviewed/Revised Date	03/16/2026
Next Review Date	03/16/2027
Origination Date	10/17/2024
Originated Department	Medical Management

Enhance External Counterpulsation (EECP)

Audience
Providers, Members, Brokers, MHC

Purpose
<p>Medical policies provide general support for applying Mountain Health Co-Op member policy document coverage decisions, and the member-specific benefit plan document must be referenced. The terms of the member-specific Policy document may differ from the standard benefit plan based on this medical policy. If there is a conflict between a member-specific policy document and the Mountain Health Co-Op medical policy, the document supersedes this policy. Any person(s) applying this medical policy must identify member eligibility, the member-specific policy document, and related policies or guidelines before applying this medical policy, including the existence of any state or federal guidance. Mountain Health Co-Op medical policies are designed for informational purposes only and are not an authorization, explanation of benefits, or contract. Receipt of benefits is subject to the satisfaction of all terms and conditions of the member-specific policy document coverage. Mountain Health Co-Op reserves the sole discretionary right to modify all policies and guidelines at any time.</p>

Definition
<p>Enhanced external counterpulsation is a noninvasive treatment (EECP) involving sequential pneumatic compression of the legs and buttocks coordinated with cardiac contractions. EECP is designed to increase diastolic aortic blood pressure, improve venous blood return, and decrease afterload on the left ventricle. EECP aims to increase perfusion during diastole in patients with chronic angina pectoris, relieving pain and reducing impairment. EECP has been studied primarily as a treatment for patients with refractory angina and heart failure, as well as for other indications such as erectile dysfunction, ischemic stroke, myocardial infarction, and cardiogenic shock.</p>

Intra-aortic balloon counterpulsation is a more familiar, invasive form of counterpulsation used as temporary circulatory assistance for the ischemic heart, often after an acute myocardial infarction. In contrast, EECP is thought to provide a permanent effect on the heart by enhancing coronary collateral development. The multiple components of the procedure include the use of the device itself, finger plethysmography to follow the blood flow, continuous electrocardiograms (ECGs) to trigger inflation and deflation, and optionally, pulse oximetry to measure oxygen saturation before and after treatment.

Policy/Procedure

Mountain Health Co-Op covers enhanced external counterpulsation (EECP) when specific medical necessity criteria are met.

1. Medically Necessity Criteria require the Member to Meet ALL of the following:

- 1.1** The member has been diagnosed with disabling angina (New York Heart Association or Canadian Cardiovascular Society Class III or IV*);
- 1.2** The member is refractory to maximum medical therapy;
- 1.3** The member is not readily amenable to surgical intervention such as percutaneous transluminal coronary angioplasty (PTCA) or cardiac bypass due to one or more of the following:
 - a)** The member's condition is inoperable
 - b)** The member is at high risk of operative complications or postoperative failure
 - c)** The member's coronary anatomy is not readily amenable to such procedures
 - d)** The member has co-morbid conditions that create excessive risk
- 1.4** The request is for no more than 35 sessions of treatment;
- 1.5** The member does not have any of the following contraindications, including but not limited to:
 - a)** Severe congestive heart failure with ejection fraction < 30%
 - b)** Aortic insufficiency
 - c)** Cardiac catheterization within 2 weeks
 - d)** Arrhythmia

2. Mountain Health Co-Op covers repeat courses of EECP medically necessary when ALL of the following criteria are met:

- 2.1** The member meets the medical necessity criteria in the previous section above;
- 2.2** Prior EECP therapy has resulted in a sustained improvement in symptoms with one or more of the following:
 - a)** An ability to stop ranolazine AND a lowered dose of, or ability to stop, other agents such as beta-blockers, calcium-channel blockers, and nitrates.
 - b)** Improvement by one or more NYHA angina classes.
 - c)** A significant (greater than 25 percent) reduction in the frequency of angina symptoms.
- 2.3** Three or more months have elapsed since the prior EECP treatment.

*New York Heart Association Functional Classification of Cardiac Disability		*Canadian Cardiovascular Society Functional Classification
Class I	No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.	Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina occurs with strenuous or rapid or prolonged exertion at work or recreation.
Class II	Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.	Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, in cold, in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.
Class III	Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.	Marked limitation of ordinary physical activity. Walking one to two blocks on the level and climbing one flight in normal conditions and at a normal pace.
Class IV	Symptoms of heart failure at rest. Any physical activity causes further discomfort.	Inability to carry on any physical activity without discomfort—anginal syndrome may be present at rest.

Source: American Heart Association, Classes of Heart Failure. 2023; Canadian Cardiovascular Society [CCS]. 1976.

Hydraulic versions of EECP devices are considered investigational and are not covered.

3. Mountain Health Co-Op considers EECP experimental and investigational for all other conditions including but not limited to the following:

- 3.1** Congestive heart failure
- 3.2** Acute retinal artery occlusion
- 3.3** Restless leg syndrome
- 3.4** Sudden deafness
- 3.5** Hepatorenal syndrome
- 3.6** Erectile dysfunction
- 3.7** Treatment of Class II angina
- 3.8** Arrhythmia
- 3.9** Aortic insufficiency
- 3.10** Peripheral vascular disease or phlebitis
- 3.11** Severe hypertension
- 3.12** Acute myocardial infarction
- 3.13** Ischemic stroke
- 3.14** Cardiogenic shock

4. Clinical Rationale

4.1 Raeissadat et al. (2018) reviewed the effectiveness of EECP in patients suffering from erectile dysfunction (ED). PubMed, Medline, Google Scholar, Trip database, Scopus, and Cochrane library databases were searched for articles with the following search terms: enhanced external counterpulsation and erectile dysfunction. No restrictions on study setting, publication date, and language were imposed. From an initial set of 208 records, 4 studies were selected after a final review. A total of 177 patients with a mean age of 59.98 years were included in these studies, with 20 to 35 hours/week of EECP treatment; 3 studies used the

International Index of Erectile Function questionnaire and 1 applied a four-item questionnaire and a peak systolic flow measurement. All of these parameters were significantly improved after the EECP treatment. To the best of their knowledge, the authors concluded that this was the first study reviewing the clinical effectiveness of EECP in patients with ED. According to the articles reviewed in this study, an improvement in erectile function following EECP treatment courses has been observed in patients with and without coronary artery disease without any significant adverse effects. Moreover, these investigators stated that since the safety and effectiveness of EECP were observed in non-controlled studies, there is a need for well-designed randomized clinical trial studies with larger sample sizes and long-term follow-up periods to evaluate this new and non-invasive therapeutic options in patients suffering from ED by excluding the confounders.

- 4.2** Zhou et al. (2021) conducted a meta-analysis of eight randomized controlled trials (RCT) to evaluate the safety and efficacy of enhanced external counterpulsation (EECP) on exercise capacity and quality of life in patients with chronic heart failure (CHF). A total of 823 participants with a mean age of 64.6 years were enrolled. Individual RCT sample sizes ranged from 40–180. Limitations were not placed on race population, religion, or gender. RCTs evaluating EECP were included if patients were diagnosed with CHF with reduced, mid-range, or preserved ejection fraction. The intervention group (n=409) received EECP for a total of either 36 hours (1 hour/day, 6 days per week, 6 weeks) or 35 hours (1 hour/day, 7 days per week, 7 weeks). The comparators (n=414) were: diet, routine nursing care, pharmacologic therapy, or sham EECP. The primary outcome measures were exercise capacity (e.g., peak VO₂, VO₂ maximum, exercise time, walking distance (six-minute walking distance), and endurance exercise) and quality of life (QOL) (e.g., Minnesota Living with Heart Failure Questionnaire (MLHFQ) and SF-36). Secondary outcome measures included: B-type natriuretic peptide, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), left ventricular ejection fraction (LVEF), and serious adverse events (SAES). Follow-up ranged from five weeks to six months. Six studies evaluated the six-minute walking distance test and found significantly improved results ($p < 0.00001$). Two studies evaluated QOL using the MLHFQ and did not find a significant improvement ($p = 0.07$). LVEF was reported in four studies and was significantly improved in the EECP group compared to the control group ($p = 0.0004$). Five studies evaluated NT-pro-BNP, and results showed significantly reduced levels in the EECP group compared to the control group ($p < 0.00001$). Two studies reported on SAES and found three events, including one patient with worsening heart failure, one with pulmonary embolism, and one with deep vein thrombosis. The author noted limitations included difficulty with treatment allocation, heterogeneity of heart failure etiology and classification, small sample sizes, and short-term follow-up. Additional high-quality studies with larger sample sizes and longer-term follow-ups are needed to assess the safety and efficacy of EECP use on patients with chronic heart failure.
- 4.3** Joli et al. (2022) noted that fatigue is one of the most presented long-term complaints in individuals previously infected with SARS-CoV-2. In a systematic review, these investigators described symptoms, etiology, possible risk factors related to post-COVID-19 fatigue, and the therapeutic approaches used to treat

post-COVID-19 fatigue. For the systematic literature search, the databases PubMed, Web of Science, Cochrane Library, and PsycInfo were employed. All studies that met the inclusion criteria were analyzed for demographics, clinical data, and treatment.

- 4.4** Included were studies that focused on an adult population (18 to 65 years of age); elderly patients and patients with chronic somatic diseases that could also cause fatigue were excluded. These researchers identified 2,851, screened 2,193, and finally included 20 studies with moderate-to-high methodological quality, encompassing 5,629 subjects. Potential risk factors for post-COVID-19 fatigue were old age, female sex, severe clinical status in the acute phase of infection, a high number of comorbidities, and a pre-diagnosis of depression/anxiety. Finally, a possible autoimmune etiology was suspected. Several therapeutic options have been tested mostly in small and uncontrolled studies: a Chinese herbal formulation improved breathlessness and fatigue.
- 4.5** Moreover, molecular hydrogen (H₂) inhalation had beneficial health effects regarding improved physical (6MWD) and respiratory function in patients with post-COVID-19. Patients also noticed an improvement in fatigue after undergoing hyperbaric oxygen therapy (HBOT) and EECP. Finally, muscle strength and physical function were improved after undergoing an 8-week bi-weekly physical therapy (PT) course, including aerobic training, strengthening exercises, diaphragmatic breathing techniques, and mindfulness training. However, the authors stated that larger and controlled studies (e.g., examining the effect of physical and/or psychotherapy for patients with post-COVID-19 fatigue) are needed.
- 4.6** May (2013) stated that enhanced ECP (EECP) is a non-invasive therapy offered to patients with angina pectoris who have unacceptable chest pain despite medical treatment and who have no operative options. During EECP, 3 sets of pneumatic cuffs wrapped around the lower extremities are inflated to a pressure of 260 to 300 mm Hg in diastole. This creates an augmented diastolic blood pressure and an increase in coronary blood flow. The therapy is usually given for 1 hour 5 days a week for 7 weeks. The author concluded that EECP is known to reduce the frequency of angina, increase the quality of life, and reduce the frequency of hospitalization.
- 4.7** Martin et al. (2014) stated that EECP improves resistance artery function in coronary artery disease patients. However, whether EECP elicits similar effects in persons with abnormal glucose tolerance (AGT) is unknown. These researchers provided novel evidence that EECP significantly improves resistance arterial function in the forearm of persons with AGT, whereas the calf only approached significance ($p \leq 0.10$). These improvements coincided with greater glycemic control, providing further insight into the potential mechanisms of EECP-mediated alterations in glycemia. These preliminary findings need to be validated by well-designed studies.
- 4.8** Badijeva et al. (2019) examined the effectiveness of EECP in treating and rehabilitating patients with stages I to IIB obliterating atherosclerosis of the lower extremities (OALE). 68 patients aged 50 to 78 years with stages I to IIB OALE in the presence of clinical symptomatology of arterial insufficiency were examined and treated. According to the treatment method, patients were divided into 2 groups: 32 people received standard drug therapy (a control group), and 36 patients had an

EECP therapy cycle during the standard therapy (a study group). The frequency of characteristic complaints, pain-free walking distance, peripheral hemodynamics, and the ankle-brachial index (ABI) were assessed. Post-treatment leg pain on walking persisted in 11 (30.6 %) and 25 (78.1 %) patients in the study group and the control group, respectively. There were leg cramps in 9 (25.0 %) and 14 (43.8 %) people and cold feet in 5 (13.9 %) and 25 (78.1 %) patients, respectively ($p < 0.05$). In the study group, the considerable increase in pain-free walking distance as compared to baseline values averaged 250 ± 31.2 m ($p < 0.05$), while that in the control group was only 64.5 ± 25.1 m ($p > 0.05$). The post-treatment increases in the leg and foot rheographic indices averaged 23.9 and 23.2 %, respectively, in the study group and 11.9 and 12.3 %, respectively, in the control group. The increases in ABI in the anterior and posterior tibial arteries were 31.4 and 35.2 %, respectively, in the study group ($p < 0.05$), and 16.0 and 13.0 %, respectively, in the control group ($p > 0.05$). The authors concluded that the findings of this study suggested that the use of EECP in the combination therapy of patients with stages I to IIb OALE was safe and effective. These preliminary findings need to be validated by well-designed studies.

4.9 Zhao et al. (2020) noted that EECP is popular in China for the treatment of coronary heart diseases, but it may be an effective treatment for other populations. In a pilot study, these researchers examined the effect of EECP on exercise endurance of healthy people and chronic obstructive pulmonary disease (COPD) patients and provided intervention measures to improve their physical condition. Patients were randomly divided into the EECP and non-EECP groups. According to their maximal oxygen uptake, the volunteers were also sub-grouped into the normal, low exercise endurance, and COPD subgroups. Differences in exercise endurance were evaluated between the EECP and non-EECP groups before and after treatment. Cardiopulmonary exercise testing included anaerobic threshold oxygen uptake (ATVO₂Kg), maximum oxygen uptake (Max-VO₂Kg), anaerobic threshold pulse (AT-O₂puls), anaerobic threshold metabolic equivalent (AT-Mets), and maximum metabolic equivalent (Max-Mets). A total of 72 volunteers were enrolled. The EECP and non-EECP groups were similar in terms of age, sex, body mass index (BMI), blood pressure, heart rate, breathing frequency, AT-VO₂Kg, Max-VO₂Kg, AT-O₂puls, AT-Mets, and Max-Mets ($p > 0.05$) before treatment. EECP significantly improved AT-VO₂Kg, MaxVO₂Kg, AT-O₂puls, AT-Mets, and Max-Mets compared with the non-EECP group ($p < 0.05$). When analyzed according to sub-groups, the AT-VO₂Kg, Max-VO₂Kg, AT-O₂puls, AT-Mets, and Max-Mets of the normal, low exercise endurance, and COPD subgroups were all significantly increased after EECP ($p < 0.05$). The authors concluded that EECP significantly improved the exercise endurance of normal adults, low-endurance adults, and COPD patients. Moreover, these researchers stated that these findings need to be validated using a large-scale, multi-center clinical trial. The drawbacks of this trial included the small sample size ($n = 13$ in the EECP COPD subgroup) and short-term follow-up. Furthermore, stratified randomization was not used.

4.10 Varanasi et al. (2021) stated that a growing number of patients diagnosed with coronavirus disease 2019 (COVID-19) have been reported to have postural orthostatic tachycardia syndrome (POTS) following the acute phase. A 57-year-old

woman was diagnosed with COVID-19 in December 2020. As a result of her acute illness, she was hospitalized for COVID-19 pneumonia and respiratory failure, followed by stays at an acute care facility and home rehabilitation center. After the acute phase, the patient was diagnosed with long-term COVID-19-associated POTS with symptoms such as fatigue, "brain fog," and dyspnea. The patient was referred to an EECF treatment center and underwent 15, 1-hour sessions over 3 weeks. Upon completion of therapy, the patient reported improvements with "brain fog" and the ability to perform activities of daily living (ADL). Her Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue score was reduced by 3 points, her six-minute walk distance (6MWD) increased by 85 feet, and her Duke Activity Status Index (DASI) improved by over 15 points. EECF therapy was chosen due to the overlap in underlying pathology driving POTS and the mechanisms of action of EECF. The authors concluded that this report was the 1st case of using EECF to successfully manage COVID-19-associated POTS and warrants further trials.

4.11 Dayrit et al. (2021) noted that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. As patients recover from COVID-19, some continue to report persisting symptoms weeks to months after acute infection. These effects have been referred to as post-acute sequelae of SARS-CoV-2 infection (PASC). These investigators reported the case of a 38-year-old woman suffering from PASC symptoms following acute COVID-19 in October 2020. During her acute infection phase, she had a home recovery and reported her predominant symptoms as fatigue, headaches, body pain, and shortness of breath. After most of her symptoms were resolved, she continued to have periodic episodes of fatigue and headaches, along with random shortness of breath while at rest and during activities for months beyond the acute phase of the illness. She also noted the presence of "brain fog" as if lacking the same clarity that she had before her illness. These symptoms persisted for 3 months before the patient underwent EECF therapy in 1-hour sessions three times per week. This therapy was chosen based on the mechanism of action of EECF benefiting patients with ischemic cardiovascular diseases. After one week, her "brain fog" improved, and her shortness of breath improved after 1.5 weeks. The patient reported returning to pre-COVID health and fitness following about 5 weeks of EECF treatment. The authors concluded that, to their knowledge, this was the 1st case of using EECF for post-COVID shortness of breath, fatigue, and "brain fog". These researchers stated that further investigation is needed to validate these findings.

4.12 In a retrospective analysis of a contemporary, consecutive patient cohort, Sathyamoorthy et al. (2022) examined the use of EECF as a possible therapy for long-term COVID-19. This trial was carried out in 7 outpatient treatment centers; the subjects received 15 to 35 EECF treatments. Main outcome measures included the change from baseline in Patient Reported Outcome Measurement Information System (PROMIS) Fatigue; Seattle Angina Questionnaire (SAQ); Duke Activity Status Index (DASI); 6MWD; Canadian Cardiovascular Society (CCS) Angina Grade; Rose Dyspnea Scale (RDS); and Patient Health Questionnaire (PHQ-9). Compared to baseline, the PROMIS Fatigue, SAQ, DASI, and 6MWD improved by 4.63 ± 3.42 ($p < 0.001$), 21.44 ± 16.54 ($p < 0.001$), 18.08 ± 13.82 ($p < 0.01$), and 200.00 ± 180.14 ($p = 0.002$), respectively. CCS and RDS improved in 63 % and 44 % of patients. All

patients unable to work before EECP were able to return post-therapy. The authors concluded that EECP significantly improved validated fatigue and cardiovascular-related markers in patients with long-term COVID-19. These researchers stated that these findings suggested that EECP may be beneficial for the management of long COVID symptoms; these promising findings are hypothesis-generating and should be further examined in a broader clinical investigation.

- 4.13** An UpToDate review on “Possibly effective emerging therapies for heart failure” (Colucci, 2015) states that “Trials and registries of EECP included some patients with HF, some of whom had improvements in their exercise capacity following EECP therapy. The PEECH trial directly evaluated the possible benefit of EECP in patients with mild-to-moderate HF. One hundred and eighty-seven patients were randomly assigned standard medical therapy with seven to eight weeks of EECP or standard medical therapy alone. Patients assigned to EECP were slightly more likely to increase their total exercise time by more than 60 seconds (35 versus 25 percent with standard medical therapy). However, EECP did not have any effect on peak VO₂. Thus, this study did not achieve positive results for its two primary endpoints. In addition, the results of this single-blind trial are subject to placebo effect. Further research will be necessary to define the impact of EECP in the treatment of HF”.
- 4.14** An UpToDate review on “COVID-19: Evaluation and management of adults with persistent symptoms following acute illness (“Long COVID”)” (Mikkelsen and Abramoff, 2022) did not mention EECP as a management/therapeutic option. UpToDate also looked at new therapies for angina pectoris (Simmons et al., 2022) and found that the efficacy of EECP was evaluated in the MUST-EECP trial, which randomly assigned 139 outpatients with angina, documented coronary artery disease, and a positive exercise tolerance test to 35 hours of active EECP using a cuff pressure of 300 mmHg or inactive counterpulsation using a cuff pressure of 75 mmHg over a four- to seven-week period of time. The following results were seen: 1) Active EECP was well tolerated without limiting side effects. 2) Exercise duration increased to a similar degree in both the active and inactive EECP groups; there was also no significant difference in nitroglycerin use. 3) Patients undergoing active EECP had a significant increase in time to ≥ 1 mm ST segment depression compared to baseline (379 versus 337 seconds), while there was no change in the inactive group. 4) More patients undergoing active EECP had a decrease in anginal episodes and fewer had an increase in angina compared to the inactive group. Similar findings have been noted in multicenter registries. In a series of 363 patients, 72 percent improved from severe to no or mild angina and 52 percent discontinued the use of nitroglycerin. At two years, the decrease in angina persisted in 55 percent of patients, survival was 83 percent, and major adverse cardiac event-free survival was 70 percent. Repeat EECP was required in 20 percent. The mechanism of these benefits is not clear but is probably related, at least in part, to improvements in stress-induced myocardial perfusion, left ventricular diastolic filling, peripheral arterial flow-mediated dilation, and endothelial function.
- 4.15** Furthermore, the 2022 American College of Cardiology (ACC)’s Expert Consensus Decision Pathway on cardiovascular sequelae of COVID-19 in adults (Gluckman et al, 2022) did not mention the use of EECP as a management option.

- 4.16** The 2012 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the management of patients with stable ischemic heart disease indicate that EECP “may be considered for relief of refractory angina.” This recommendation is based on Class IIb, Level of Evidence: B, which indicates that the intervention's efficacy is not well established and that further studies would be helpful.
- 4.17** The 2014 American College of Cardiology/American Heart Association (ACC/AHA) issued a Focused Update on the 2012 guideline on diagnosing and managing patients with stable ischemic heart disease in which they specifically reviewed their recommendation on EECP. Based on their review, the recommendation on EECP remains unchanged from the 2012 guideline.
- 4.18** Medicare has published a national coverage decision on EECP that mandates coverage for the following indications: "Coverage is provided for the use of ECP [external counterpulsation] for patients who have been diagnosed with disabling angina who, in the opinion of a cardiologist or cardiothoracic surgeon, are not readily amenable to surgical intervention, such as percutaneous transluminal coronary angioplasty or cardiac bypass because: 1) Their condition is inoperable, or at high risk of operative complications or post-operative failure; 2) Their coronary anatomy is not readily amendable to such procedures; or 3) They have co-morbid states which create excessive risk." Medicare's coverage decision also noted that while the U.S. Food and Drug Administration has cleared EECP "for use in treating a variety of cardiac conditions, including stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock, the use of this device to treat cardiac conditions other than stable angina pectoris is not covered...."
- 4.19** The FDA approved 510(k) the CardiAssist™ External Counterpulsation (ECP) System in 1980. Since then, additional ECP devices, including but not limited to: Soulaire External Counterpulsation System, Enhanced External Counterpulsation Device Plus Omay-A, and Pure Flow External Counterpulsation Device have received 510(k) approval for use in treating stable and unstable angina pectoris, acute MI, cardiogenic shock, and CHF (FDA, 2020a; FDA, 2020b; FDA, 2018; FDA, 2016).

Applicable Coding

CPT Codes

92971 Cardioassist-method of circulatory assist; external [when specified as outpatient EECP]

HCPCS Codes

G0166 External counterpulsation, per treatment session

Vendors

- Personify
- HPS

References

1. American Heart Association (AHA). 2023. "Classes and Stages of Heart Failure". <https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure>
2. Badtieva VA, Voroshilova DN, Sichinava NV. Use of enhanced external counterpulsation in the treatment and rehabilitation of patients with atherosclerosis obliterans of the lower extremity. *Vopr Kurortol Fizioter Lech Fiz Kult.* 2019;96(4):5-11.
3. Center for Medicare & Medicaid Services (CMS). National Coverage Determination for external counterpulsation (ECP) therapy for severe angina (20.20). 2006; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=97&ncdver=2>
4. CMS National Coverage Determination (NCD) for External Counterpulsation Therapy for Severe Angina (20.20) accessed on 7/29/2020 at: <https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=97&ncdver=2&DocID=20.20&bc=gAAAAAgAAAA AAA%3d%3d&>
5. Colucci WS. Investigational and emerging therapies for heart failure. *UpToDate* [online serial]. Waltham, MA
6. Dayrit JK, Verduzco-Gutierrez M, Teal A, Shah SA. Enhanced external counterpulsation as a novel treatment for post-acute COVID-19 sequelae. *Cureus.* 2021;13(4):e14358.
7. Fihn, S. D., J. C. Blankenship, K. P. Alexander, J. A. Bittl, J. G. Byrne, B. J. Fletcher, G. C. Fonarow, R. A. Lange, G. N. Levine, T. M. Maddox, S. S. Naidu, E. M. Ohman and P. K. Smith (2014). "2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons." *J Am Coll Cardiol* 64(18): 1929-1949.
8. Fihn, S. D., J. M. Gardin, J. Abrams, K. Berra, J. C. Blankenship, A. P. Dallas, P. S. Douglas, J. M. Foody, T. C. Gerber, A. L. Hinderliter, S. B. King, 3rd, P. D. Kligfield, H. M. Krumholz, R. Y. Kwong, M. J. Lim, J. A. Linderbaum, M. J. Mack, M. A. Munger, R. L. Prager, J. F. Sabik, L. J. Shaw, J. D. Sikkema, C. R. Smith, Jr., S. C. Smith, Jr., J. A. Spertus, S. V. Williams, J. L. Anderson and F. American College of Cardiology Foundation/American Heart Association Task (2012). "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons." *Circulation* 126(25): e354-471.
9. Joli J, Buck P, Zipfel S, Stengel A. Post-COVID-19 fatigue: A systematic review. *Front Psychiatry.* 2022;13:947973.
10. Martin JS, Beck DT, Braith RW. Peripheral resistance artery blood flow in subjects with abnormal glucose tolerance is improved following enhanced external counterpulsation therapy. *Appl Physiol Nutr Metab.* 2014;39(5):596-599.
11. May O. Enhanced external counterpulsation therapy for patients with angina pectoris. *Ugeskr Laeger.* 2013;175(3):116-119.
12. Mikkelsen ME, Abramoff B. COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID"). *UpToDate* [online serial]. Waltham, MA
13. Raeissadat SA, Javadi A, Allameh F. Enhanced external counterpulsation in rehabilitation of erectile dysfunction: A narrative literature review. *Vasc Health Risk Manag.* 2018;14:393-399.
14. Sathyamoorthya M, Verduzco-Gutierrez M, Varanasic S, et al. Enhanced external counterpulsation for management of symptoms associated with long COVID. *Am Heart J Plus Cardiol Res Pract.* 2022b(13):100105.
15. Simmons M, Laham RJ. (2022). *UpToDate, Inc.* "New Therapies for Angina Pectoris". Topic 1524. Version 44.0. Accessed December 5, 2023. <https://www.uptodate.com>
16. United States Food and Drug Administration (FDA). 510(k) summary. *CardiAssist External Counterpulsation.* K792430. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K792430>

17. United States Food and Drug Administration (FDA). 510(k) summary. Enhanced External Counterpulsation Device Plus OmayA. K191955.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K191955>
18. United States Food and Drug Administration (FDA). 510(k) summary. External Counterpulsation System, Soulaire. K202108. Decision Date August 28, 2020b. Accessed Mar 8, 2023. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K202108>
19. United States Food and Drug Administration (FDA). 510(k) summary. Pure Flow External Counterpulsation Device. K173483.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173483>
20. United States Food and Drug Administration (FDA). Product Classification DRN.
21. Varanasi S, Sathyamoorthy M, Chamakura S, Shah SA. Management of long-COVID postural orthostatic tachycardia syndrome with enhanced External counterpulsation. Cureus. 2021;13(9):e18398.
22. Writing Committee; Gluckman TJ, Bhavne NM, Allen LA, et al. 2022 ACC Expert Consensus Decision Pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection and return to play: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717-1756
23. Zhao M, Huang Y, Li L, et al. Enhanced external counterpulsation efficacy on exercise endurance in COPD patients and healthy subjects: A pilot randomized clinical trial. Int J Chron Obstruct Pulmon Dis. 2020;15:25-31.
24. Zhou ZF, Wang DJ, Li XM, Zhang CL, Wu CY. Effects of enhanced external counterpulsation on exercise capacity and quality of life in patients with chronic heart failure: A meta-analysis. Medicine (Baltimore). 2021 Jul 9;100(27):e26536.

Review/Revision/Approval History	
Date	Description
10/27/2024	NEW
3/16/2026	Revised by Mountain Health CO-OP Policy Committee

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult appropriate healthcare providers for medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s benefit plan, effective when services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Including or excluding a procedure, diagnosis, or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as they apply to an individual member.

Mountain Health Co-Op makes no representations and accepts no liability regarding the content of any external information cited or relied upon in this policy. Mountain Health Co-Op updates its Coverage Policies regularly and reserves the right to amend these policies and give notice per State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Mountain Health Co-Op.

”Mountain Health Co-Op” and its accompanying logo and marks are protected and registered trademarks of Mountain Health Co-Op. The content of this Service is proprietary and protected by copyright. You may access the copyrighted content of this Service only for purposes outlined in these Conditions of Use.

© CPT Only – American Medical Association